TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A

Vaccine

Volumn 25, Issue 22, 2007, Pages 4401-4409

  Zughaier, Susu ^a   Steeghs, Liana ^c   van der Ley, Peter ^d   Stephens, David S ^a,b  

^a Division of Infectious Diseases   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UTRECHT UNIVERSITY   (Netherlands)

^d NETHERLANDS VACCINE INSTITUTE   (Netherlands)

Author keywords

Adjuvanticity; IgG titer; Lipid A; TLR4

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; LIPID A; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG ACTIVITY; HUMAN; HUMAN CELL; MACROPHAGE; MOUSE; NEISSERIA MENINGITIDIS; NEISSERIACEAE INFECTION; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; HUMANS; IMMUNOGLOBULIN G; LIPID A; MACROPHAGES; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED C3H; NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS, SEROGROUP B; TOLL-LIKE RECEPTOR 4;

EID: 34247631624     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.03.029     Document Type: Article

References (47)

1. Rosenstein N.E., Perkins B.A., Stephens D.S., Lefkowitz L., Cartter M.L., Danila R., et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 180 6 (1999) 1894-1901
2. van Deuren M., Brandtzaeg P., and van der Meer J.W. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev 13 1 (2000) 144-166
3. Rosenstein N.E., Fischer M., and Tappero J.W. Meningococcal vaccines. Infect Dis Clin N Am 15 1 (2001) 155-169
4. Steeghs L., de Cock H., Evers E., Zomer B., Tommassen J., and van der Ley P. Outer membrane composition of a lipopolysaccharide-deficient Neisseria meningitidis mutant. EMBO J 20 24 (2001) 6937-6945
5. Quakyi E.K., Frasch C.E., Buller N., and Tsai C.M. Immunization with meningococcal outer-membrane protein vesicles containing lipooligosaccharide protects mice against lethal experimental group B Neisseria meningitidis infection and septic shock. J Infect Dis 180 3 (1999) 747-754
6. Steeghs L., Kuipers B., Hamstra H.J., Kersten G., van Alphen L., and van der Ley P. Immunogenicity of outer membrane proteins in a lipopolysaccharide-deficient mutant of Neisseria meningitidis: influence of adjuvants on the immune response. Infect Immun 67 10 (1999) 4988-4993
7. van der Ley P., Steeghs L., Hamstra H.J., ten Hove J., Zomer B., and van Alphen L. Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun 69 10 (2001) 5981-5990
8. Steeghs L., Tommassen J., Leusen J.H., van de Winkel J.G., and van der Ley P. Teasing apart structural determinants of 'toxicity' and 'adjuvanticity': implications for meningococcal vaccine development. J Endotoxin Res 10 2 (2004) 113-119
9. Tzeng Y.L., Datta A., Kolli V.K., Carlson R.W., and Stephens D.S. Endotoxin of Neisseria meningitidis composed only of intact lipid A: inactivation of the meningococcal 3-deoxy-d-manno-octulosonic acid transferase. J Bacteriol 184 9 (2002) 2379-2388
10. Zughaier S.M., Tzeng Y.L., Zimmer S.M., Datta A., Carlson R.W., and Stephens D.S. Neisseria meningitidis lipooligosaccharide structure-dependent activation of the macrophage CD14/Toll-like receptor 4 pathway. Infect Immun 72 1 (2004) 371-380
11. Zughaier S.M., Zimmer S.M., Datta A., Carlson R.W., and Stephens D.S. Differential induction of the toll-like receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins. Infect Immun 73 5 (2005) 2940-2950
12. Zughaier S., Agrawal S., Stephens D.S., and Pulendran B. Hexa-acylation and KDO(2)-glycosylation determine the specific immunostimulatory activity of Neisseria meningitidis lipid A for human monocyte derived dendritic cells. Vaccine 24 9 (2006) 1291-1297
13. Kahler C.M., Carlson R.W., Rahman M.M., Martin L.E., and Stephens D.S. Two glycosyltransferase genes, lgtF and rfaK, constitute the lipooligosaccharide ice (inner core extension) biosynthesis operon of Neisseria meningitidis. J Bacteriol 178 23 (1996) 6677-6684
14. York WS, Darvill AG, McNeil M, Stevenson TT, Albersheim P. Isolation and characterization of plant cell walls and cell wall components. Methods Emzymol 1985;118:3-40.
15. Fukuoka S., Kamishima H., Nagawa Y., Nakanishi H., Ishikawa K., Niwa Y., et al. Structural characterization of lipid A component of Erwinia corotovora lipopolysaccharide. Arch Microbiol 157 (1992) 311-318
16. Steeghs L., den Hartog R., den Boer A., Zomer B., Roholl P., and van der Ley P. Meningitis bacterium is viable without endotoxin. Nature 392 6675 (1998) 449-450
17. Park E., Quinn M.R., Wright C.E., and Schuller-Levis G. Taurine chloramine inhibits the synthesis of nitric oxide and the release of tumor necrosis factor in activated RAW 264.7 cells. J Leukoc Biol 54 2 (1993) 119-124
18. Jodar L., Feavers I.M., Salisbury D., and Granoff D.M. Development of vaccines against meningococcal disease. Lancet 359 9316 (2002) 1499-1508
19. Kahler C.M., Martin L.E., Shih G.C., Rahman M.M., Carlson R.W., and Stephens D.S. The (α2 → 8)-linked polysialic acid capsule and lipooligosaccharide structure both contribute to the ability of serogroup B Neisseria meningitidis to resist the bactericidal activity of normal human serum. Infect Immun 66 12 (1998) 5939-5947
20. Aase A., Naess L.M., Sandin R.H., Herstad T.K., Oftung F., Holst J., et al. Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine 21 17-18 (2003) 2042-2051
21. Oster P., Lennon D., O'Hallahan J., Mulholland K., Reid S., and Martin D. MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 23 17-18 (2005) 2191-2196
22. Schromm A.B., Brandenburg K., Loppnow H., Moran A.P., Koch M.H., Rietschel E.T., et al. Biological activities of lipopolysaccharides are determined by the shape of their lipid A portion. Eur J Biochem 267 7 (2000) 2008-2013
23. Seydel U., Schromm A.B., Blunck R., and Brandenburg K. Chemical structure, molecular conformation, and bioactivity of endotoxins. Chem Immunol 74 (2000) 5-24
24. Tamai R., Asai Y., Hashimoto M., Fukase K., Kusumoto S., Ishida H., et al. Cell activation by monosaccharide lipid A analogues utilizing Toll-like receptor 4. Immunology 110 1 (2003) 66-72
25. Stover A.G., Da Silva Correia J., Evans J.T., Cluff C.W., Elliott M.W., Jeffery E.W., et al. Structure-activity relationship of synthetic toll-like receptor 4 agonists. J Biol Chem 279 6 (2004) 4440-4449
26. + channel in transmembrane signaling. J Immunol 166 2 (2001) 1009-1015
27. Brandenburg K., Kusumoto S., and Seydel U. Conformational studies of synthetic lipid A analogues and partial structures by infrared spectroscopy. Biochim Biophys Acta 1329 1 (1997) 183-201
28. Muroi M., and Tanamoto K. The polysaccharide portion plays an indispensable role in Salmonella lipopolysaccharide-induced activation of NF-kappaB through human toll-like receptor 4. Infect Immun 70 11 (2002) 6043-6047
29. Uronen-Hansson H., Steeghs L., Allen J., Dixon G.L., Osman M., van der Ley P., et al. Human dendritic cell activation by Neisseria meningitidis: phagocytosis depends on expression of lipooligosaccharide (LOS) by the bacteria and is required for optimal cytokine production. Cell Microbiol 6 7 (2004) 625-637
30. Steeghs L., van Vliet S.J., Uronen-Hansson H., van Mourik A., Engering A., Sanchez-Hernandez M., et al. Neisseria meningitidis expressing lgtB lipopolysaccharide targets DC-SIGN and modulates dendritic cell function. Cell Microbiol 8 2 (2006) 316-325
31. Ismaili J., Rennesson J., Aksoy E., Vekemans J., Vincart B., Amraoui Z., et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J Immunol 168 2 (2002) 926-932
32. De Becker G., Moulin V., Pajak B., Bruck C., Francotte M., Thiriart C., et al. The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. Int Immunol 12 6 (2000) 807-815
33. Moore A., McCarthy L., and Mills K.H. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 17 20-21 (1999) 2517-2527
34. Naess L.M., Aarvak T., Aase A., Oftung F., Hoiby E.A., Sandin R., et al. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Vaccine 17 7-8 (1999) 754-764
35. Johnson A.G., Gaines S., and Landy M. Studies on the O antigen of Salmonella typhosa. V. Enhancement of antibody response to protein antigens by the purified lipopolysaccharide. J Exp Med 103 2 (1956) 225-246
36. Steeghs L., Berns M., ten Hove J., de Jong A., Roholl P., van Alphen L., et al. Expression of foreign LpxA acyltransferases in Neisseria meningitidis results in modified lipid A with reduced toxicity and retained adjuvant activity. Cell Microbiol 4 9 (2002) 599-611
37. Durand V., Wong S.Y., Tough D.F., and Le Bon A. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta. Immunol Cell Biol 82 6 (2004) 596-602
38. Ovary Z. Recent insight into class-specific properties of murine immunoglobulins obtained with the help of monoclonal antibodies. Int Arch Allergy Appl Immunol 69 4 (1982) 385-392
39. Kenney J.S., Hughes B.W., Masada M.P., and Allison A.C. Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J Immunol Methods 121 2 (1989) 157-166
40. Paoletti L.C., and Kasper D.L. Conjugate vaccines against group B Streptococcus types IV and VII. J Infect Dis 186 1 (2002) 123-126
41. Paoletti L.C., Pinel J., Kennedy R.C., and Kasper D.L. Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate. J Infect Dis 181 2 (2000) 653-658
42. Baker C.J., Paoletti L.C., Rench M.A., Guttormsen H.K., Edwards M.S., and Kasper D.L. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. J Infect Dis 189 6 (2004) 1103-1112
43. Hoebe K., Janssen E.M., Kim S.O., Alexopoulou L., Flavell R.A., Han J., et al. Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat Immunol 4 12 (2003) 1223-1229
44. Miyake K. Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends Microbiol 12 4 (2004) 186-192
45. Akira S., and Takeda K. Toll-like receptor signalling. Nat Rev Immunol 4 7 (2004) 499-511
46. Kahler C.M., and Stephens D.S. Genetic basis for biosynthesis, structure, and function of meningococcal lipooligosaccharide (endotoxin). Crit Rev Microbiol 24 4 (1998) 281-334
47. Shih G.C., Kahler C.M., Carlson R.W., Rahman M.M., and Stephens D.S. gmhX, a novel gene required for the incorporation of l-glycero-d-manno-heptose into lipooligosaccharide in Neisseria meningitidis. Microbiology 147 Pt 8 (2001) 2367-2377